NXTC NextCure
- 1.420
- +0.050+3.65%
- 1.420
- 0.0000.00%
NextCure News
Express News | HC Wainwright & Co. reaffirmed its buy rating for NextCure (NXTC.US) and adjusted its target price from $8.00 to $8.00.
HC Wainwright & Co. Reiterates Buy on NextCure, Maintains $8 Price Target
HC Wainwright & Co. analyst Emily Bodnar reiterates NextCure (NASDAQ:NXTC) with a Buy and maintains $8 price target.
Buy Rating Affirmed on NextCure's NC410 Promising Clinical Outcomes in MSS-CRC and Ovarian Cancer
NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024
Of the evaluable ICI-naïve MSS/MSI-L CRC patients without liver metastasis, there were 2 confirmed ongoing PRs and a disease control rate of 51%Of the 7 evaluable ovarian cancer patients, there were 3 PRs and a disease
NextCure Price Target Maintained With a $8.00/Share by HC Wainwright & Co.
NextCure Price Target Maintained With a $8.00/Share by HC Wainwright & Co.
Needham: Reiterates the NextCure (NXTC.US) rating and adjusted from buy to buy rating, target price is $4.00.
Needham: Reiterates the NextCure (NXTC.US) rating and adjusted from buy to buy rating, target price is $4.00.
Needham Reiterates Buy on NextCure, Maintains $4 Price Target
Needham analyst Gil Blum reiterates NextCure with a Buy and maintains $4 price target.
Buy Rating Affirmed for NextCure Amid Promising Oncology Treatment Prospects and Solid Financials
Promising Clinical Trial Results Position NextCure's NC410 as a Potential Game-Changer in Cancer Treatment
NextCure (NXTC.US): The 2024 Q1 financial report achieved revenue of $0, with a previous value of $0; earnings per share of -0.61 dollars, previous value of -0.58 dollars, expected value of -0.59 dollars.
NextCure (NXTC.US): The 2024 Q1 financial report achieved revenue of $0, with a previous value of $0; earnings per share of -0.61 dollars, previous value of -0.58 dollars, expected value of -0.59 dollars.
NextCure Q1 EPS $(0.61) Misses $(0.59) Estimate
NextCure (NASDAQ:NXTC) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.59) by 3.39 percent. This is a 5.17 percent decrease over losses of $(0.58) per
NextCure 1Q Loss/Shr 61c >NXTC
NextCure 1Q Loss/Shr 61c >NXTC
Press Release: NextCure Provides Business Update and Reports First Quarter 2024 Financial Results
NextCure Provides Business Update and Reports First Quarter 2024 Financial Results -- Phase 1b data for NC410 combo with pembro to be presented at ASCO annual meeting on June 1 -- Present
NextCure to Present Phase 1b Data of NC410 in Combination With Pembrolizumab at ASCO 2024
BELTSVILLE, Md., April 24, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to
Promising Clinical Outlook for NextCure's Novel ADC LNCB74 Spurs Buy Rating
NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024
Poster presentation highlights strong safety and pharmacokinetic profiles for LNCB74BELTSVILLE, Md., April 08, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceuti
Press Release: NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board
NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board BELTSVILLE, Md., April 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed
NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference
12 Health Care Stocks Moving In Friday's After-Market Session
GainersSalarius Pharmaceuticals (NASDAQ:SLRX) shares rose 33.9% to $0.83 during Friday's after-market session. The market value of their outstanding shares is at $3.2 million. Masimo (NASDAQ:MASI) sha
NextCure Is Maintained at Buy by HC Wainwright & Co.
NextCure Is Maintained at Buy by HC Wainwright & Co.
Analysis
Price Target
No Data
